22 May 2013
Keywords: USA, Overactive bladder drug market, Frost & Sullivan, Mirabegron
Article | 14 May 2010
The USA’s overactive bladder (OAB) treatment market is slated to witness strong growth, fuelled by the increase in diagnosed ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 May 2010
13 May 2010
21 May 2013
© 2013 thepharmaletter.com